Medtronic PLC $MDT Shares Sold by Robeco Schweiz AG

Robeco Schweiz AG cut its stake in shares of Medtronic PLC (NYSE:MDT) by 21.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 97,342 shares of the medical technology company’s stock after selling 27,252 shares during the period. Robeco Schweiz AG’s holdings in Medtronic were worth $9,271,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Delos Wealth Advisors LLC purchased a new position in Medtronic in the 2nd quarter valued at $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic in the 3rd quarter worth $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic in the third quarter valued at about $33,000. Tripletail Wealth Management LLC acquired a new position in shares of Medtronic during the third quarter worth about $34,000. Finally, GFG Capital LLC purchased a new position in Medtronic during the second quarter worth about $36,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

Medtronic stock opened at $96.46 on Wednesday. The stock has a fifty day moving average price of $98.56 and a 200 day moving average price of $94.72. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a market capitalization of $123.67 billion, a P/E ratio of 26.00, a PEG ratio of 2.56 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of analyst reports. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Royal Bank Of Canada boosted their price objective on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, Barclays boosted their price target on Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).